NYON, Switzerland, August 25 /PRNewswire/ -- Mymetics Corporation (OTC: MYMX), will be holding an important conference call on Wednesday August 27th 2008 at 1 PM New York Time to update all shareholders on the recent progress of the company, the June 30th 2008 Form 10-Q and to address recent press articles.

You may join the call Toll Free from the US at +1-866-591-4361 PIN 815 726 and from Europe at +41-800-329-326 PIN 815 726.

Corporate description:

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trials. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.

Contact: Anthony Jessop Senior Vice President Mymetics, Inc. Phone North America: +1-303-800-6606 E-Mail: ajessop@mymetics.com

Contact: Anthony Jessop, Senior Vice President Mymetics, Inc., Phone North America: +1-303-800-6606, E-Mail: ajessop@mymetics.com